OrthoPediatrics/$KIDS
1D1W1MYTD1Y5YMAX
Capital at risk
About OrthoPediatrics
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
- Ticker
- $KIDS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 602
- Headquarters
- Warsaw, United States
- Website
- www.orthopediatrics.com
OrthoPediatrics Metrics
BasicAdvanced
$583M
-
-$1.67
0.96
-
Price and volume
Market cap
$583M
Beta
0.96
52-week high
$26.74
52-week low
$14.42
Average daily volume
253K
Financial strength
Current ratio
4.778
Quick ratio
2.021
Long term debt to equity
0.316
Total debt to equity
0.317
Interest coverage (TTM)
-2.72%
Profitability
EBITDA (TTM)
-0.445
Gross margin (TTM)
73.65%
Net profit margin (TTM)
-15.72%
Operating margin (TTM)
-9.01%
Effective tax rate (TTM)
-0.70%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-2.80%
Return on equity (TTM)
-11.36%
Valuation
Price to revenue (TTM)
2.097
Price to book
1.7
Price to tangible book (TTM)
3.93
Price to free cash flow (TTM)
-288.783
Free cash flow yield (TTM)
-0.35%
Free cash flow per share (TTM)
-0.077
Growth
Revenue change (TTM)
14.49%
Earnings per share change (TTM)
-6.78%
3-year revenue growth (CAGR)
22.62%
3-year earnings per share growth (CAGR)
236.23%
What the Analysts think about OrthoPediatrics
Analyst ratings (Buy, Hold, Sell) for OrthoPediatrics stock.
Analyst projections of the future price of OrthoPediatrics stock.
Bulls say / Bears say
Recorded a new Q2 2026 revenue high of $70.5 million, up 15% year-over-year, driven by strong demand in trauma, deformity, and OPSB product lines (Reuters)
Trauma & Deformity revenue surged 26% year-over-year to $52.6 million in Q2 2026, fueled by expanded adoption of core implants and the late-June launch of the 3P Hip system (Reuters)
Raised full-year 2026 revenue guidance to $265 million–$269 million, a $2 million increase at both ends, while reiterating targets of ~$25 million in adjusted EBITDA and free cash flow breakeven (Reuters)
Continued GAAP net loss of $7.2 million in Q2 2026 underscores that OrthoPediatrics has yet to achieve profitability at the operating level (Reuters)
Scoliosis segment revenue declined 9% year-over-year to $16.9 million in Q2 2026, reflecting timing issues in set placements and lower OUS sales (Reuters)
Despite a 78% improvement, OrthoPediatrics still consumed $3.1 million of free cash flow in Q2 2026, highlighting ongoing cash burn to fund growth initiatives (SEC)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2026.
OrthoPediatrics Financial Performance
Revenues and expenses
OrthoPediatrics Earnings Performance
Company profitability
Upcoming events
No upcoming events
OrthoPediatrics News
AllArticlesVideos
Funds containing OrthoPediatrics
Fund name | Fund size | $KIDS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.